New drug may cut infections after Half-Matched stem cell transplants
NCT ID NCT04237623
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 30 times
Summary
This study tests whether a drug called sargramostim can help the body rebuild its infection-fighting cells faster after a special type of stem cell transplant for blood cancers. About 38 adults with cancers like leukemia or lymphoma will receive the drug after a half-matched donor transplant. The goal is to see if it works as well as the standard drug and might lower the risk of serious infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSPLANT-RELATED HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northside Hospital
RECRUITINGAtlanta, Georgia, 30342, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.